By Fineline Cube 
China-based Guangxi Wuzhou Zhongheng Group Co., Ltd. (SHA: 600252) announced that its wholly-owned subsidiary, Zhongheng Innovation, has acquired the patent for LZ-01, a Class 1 innovative chemical drug for the treatment of chronic heart failure. The acquisition, valued at RMB 55 million, was completed through a public listing on the Shanghai Technology Exchange from China Rongtong Scientific Research Institute Group Co., Ltd. The “Technology (Patent Rights) Transfer Contract” was signed on August 1.
Acquisition Details
Under the contract, Zhongheng Innovation will pay the transfer fee in phased milestone payments. Zhongheng Innovation will be responsible for the IND/NDA submissions, clinical registration, and process validation. The original rights holder will assist with document preparation, technical handover, and regulatory review responses.
LZ-01 Development
LZ-01, discovered by the Naval Medical University of the Chinese People’s Liberation Army, is a compound with a novel target. It has the potential to significantly improve cardiac function and myocardial remodeling in chronic heart failure. The drug is administered orally and currently has no similar products on the market in China or abroad. It is in the preclinical research stage and shows significant therapeutic advantages for chronic heart failure with reduced ejection fraction.
Mechanism and Innovation
LZ-01 focuses on enhancing myocardial tissue energy metabolism, setting it apart from existing treatments that primarily inhibit the neuro-humoral system. This innovative mechanism is expected to address an unmet clinical need in the treatment of chronic heart failure.-Fineline Info & Tech